BioCentury | Mar 2, 2015
Strategy

Sosei finds its R&D engine

...conjunctivitis; and APP13007, an undisclosed ophthalmic solution for inflammatory eye diseases. Last December, Sosei acquired Jitsubo Co. Ltd....
...drug discovery capabilities. The nanoparticle technology will allow the group to screen insoluble compounds, while Jitsubo...
BioCentury | Dec 15, 2014
Company News

Jitsubo, Sosei deal

...Sosei acquired a 52.4% stake in Jitsubo for Y431 million ($3.7 million). Sosei acquired 69,490 existing...
...69,490 existing shares and 68,871 new shares of Jitsubo, which became a subsidiary. Sosei said Jitsubo's...
...Molecular Hiving, and molecule modification technology, Peptune, will allow Sosei to enter the peptide market. Jitsubo...
Items per page:
1 - 2 of 2
BioCentury | Mar 2, 2015
Strategy

Sosei finds its R&D engine

...conjunctivitis; and APP13007, an undisclosed ophthalmic solution for inflammatory eye diseases. Last December, Sosei acquired Jitsubo Co. Ltd....
...drug discovery capabilities. The nanoparticle technology will allow the group to screen insoluble compounds, while Jitsubo...
BioCentury | Dec 15, 2014
Company News

Jitsubo, Sosei deal

...Sosei acquired a 52.4% stake in Jitsubo for Y431 million ($3.7 million). Sosei acquired 69,490 existing...
...69,490 existing shares and 68,871 new shares of Jitsubo, which became a subsidiary. Sosei said Jitsubo's...
...Molecular Hiving, and molecule modification technology, Peptune, will allow Sosei to enter the peptide market. Jitsubo...
Items per page:
1 - 2 of 2